Dermatology startup Dermira raises $42M in Series A and acquires Valocor Therapeutics
This article was originally published in Scrip
Executive Summary
Dermira Inc, a new company focusing on the dermatology arena including an early-stage acne therapy candidate, has raised $42 million in a Series A round, which includes existing investor Bay City Capital, along with New Enterprise Associates and Canaan Partners. In conjunction with the fund raising, Dermira has acquired the dermatology company Velocor Therapeutics for an undisclosed sum, and it will continue to seek out other dermatological assets for licensing or acquisition.